CLOs on the Move

RotaChrom

www.rotachrom.com

 
RotaChrom Technologies is the inventor and first worldwide manufacturer of the Industrial Scale Centrifugal Partition Chromatography (iCPC) platforms. The company revolutionizes the pharmaceutical and cannabis industries by manufacturing and selling unique inventions of a special purifying technology. A cost-efficient and easily adaptable separation solution is offered for active pharmaceutical ingredients (API) and cannabinoids. The cost and the risk profile of R&D, as well as production can be significantly lower by using CPC tools, thereby pharmaceutical and cannabis-based products can become more widely available. Since its establishment, the company has achieved massive international success in pharmaceutical and pharma-graded cannabis purification. It has ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rotachrom.com
  • 300 Spectrum Center Drive
    Irvine, CA USA 92618
  • Phone: 661.768.2247

Executives

Name Title Contact Details

Similar Companies

Rx Systems

Rx Systems is a Saint Charles, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hi-School Pharmacy

Hi-School Pharmacy is a Vancouver, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignite Mental Health

Join us in the fight to end the mental health crisis plaguing our campuses and transform the future of mental health.

Ocusoft

Ocusoft is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.